There are fewer studies focused on TRH’s role in the treatment of MS; nevertheless, it is known that TRH expression increases in demyelinating injury sites, as well as in axonal transections (i.e., the main pathological features of MS) [62]. This evidence concerns the gene TRH and myeloid sarcoma.